tbuckley/cabot-search huggingface dataset:
Costs of Treatment for Elderly Women With Early-Stage Breast Cancer in Fee-for-Service Settings
Authors: Joan L. Warren, Martin L. Brown, Michael P. Fay, Nicola Schussler, Arnold L. Potosky, Gerald F. Riley
Journal: Journal of Clinical Oncology (2002)

PURPOSE: This study provides population-based estimates of the treatment costs for elderly women with early-stage breast cancer, with emphasis on costs of modified radical mastectomy (MRM) compared with breast-conserving surgery (BCS) and radiation therapy (RT). PATIENTS AND METHODS: Women with breast cancer from the Surveillance, Epidemiology, and End Results cancer registries were linked with their Medicare claims, 1990 through 1998. Each claim was assigned to an initial, continuing, or terminal care phase after a cancer diagnosis. Mean monthly phase-specific costs were determined for all health care and for treatment related only to cancer. Cumulative long-term costs of care that accrue during a women’s remaining lifetime were calculated by treatment group. RESULTS: Initial care costs for the 6 months after diagnosis for women who underwent BCS with RT were approximately $450 per month higher than for women with MRM. During the continuing-care phase, costs for women undergoing BCS with RT were significantly less expensive than for MRM cases. The two groups had similar costs in the terminal-care phase. Assuming the same survival distributions, long-term costs for women undergoing BCS with RT were not statistically different than for women undergoing MRM. CONCLUSION: Although mastectomy was less costly in the initial phase, the lifetime costs of BCS with RT and mastectomy were equivalent. Thus, women’s preferences, resources to cover out-of-pocket costs, and life situations should be the major factors addressed in shared decision making about treatment options.
Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for AMG 479 (A479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC).
Authors: J. Lu, H. Deng, R. Tang, C. Hsu, H. L. Kindler, C. Fuchs, J. Gansert, S. Bray, E. Loh, M. Zhu
Journal: Journal of Clinical Oncology (2011)

263 Background: A479 is an investigational, fully human monoclonal antibody against IGF1R. In a phase II study, 125 pts with mPC were randomized 1:1:1 to A479, placebo (P), or conatumumab in combination with G. Addition of A479 (12 mg/kg IV, Q2W) to G (1000 mg/m 2 ) showed evidence of improved OS and PFS (Kindler, JCO 2010:28 abstr 4035). An E-R analysis was done to inform P3 dose selection for A479. Methods: A population PK model of A479 was constructed using data from multiple studies. An E-R analysis was performed with pts from the A479+G and P+G arms (∼40 pts/arm). The effect of estimated steady-state area under the curve (AUC ss ) on OS and PFS was evaluated with a Cox proportional hazard model. Effects of potential confounding factors on OS- AUC ss and PFS-AUC ss associations were assessed by multivariate analysis. Exposure-safety data were analyzed with descriptive statistics and linear regression. P3 doses for A479 were explored with Monte Carlo simulations using population PK and parametric survival models. Results: There was a positive association between OS or PFS and higher AUC ss in the A479+G arm (P&lt;0.001, &lt;0.001) that remained even when data from the A479+G and P+G arms were combined (P=0.033, 0.022). Pts with AUC ss ≥ median (19.2 mg·h/μL) had longer median OS and PFS (16.0, 7.6 months) than pts with AUC ss &lt; median (4.7, 1.9 months). OS-AUC ss and PFS-AUC ss associations were significant after adjusting for potential confounding factors. Sensitivity E-R analyses were done to confirm the modeling results. The incidence of most adverse events was similar between the AUC ss &lt; and ≥ median groups, although the incidence of grade ≥3 hyperglycemia, neutropenia, and thrombocytopenia trended higher in pts with AUC ss ≥ median. Population PK indicated 1.7-fold higher clearance of A479 in mPC than non-mPC pts. No G-A479 PK interactions were identified. PK simulations showed similar AUC ss of A479 in mPC pts at 20 mg/kg and in non-mPC pts at 12 mg/kg. Simulations projected improved OS and PFS with 20 mg/kg vs 12 mg/kg A479. Conclusions: Increased exposure to A479 is associated with improved clinical outcomes in mPC. This supports the evaluation of 20 mg/kg A479 in P3. [Table: see text]
Alzheimer disease -amyloid activity mimics cholesterol oxidase
Authors: L. Puglielli, A. L. Friedlich, K. D.R. Setchell, S. Nagano, C. Opazo, R. A. Cherny, K. J. Barnham, J. D. Wade, S. Melov, D. M. Kovacs, A. I. Bush
Journal: Journal of Clinical Investigation (2006)
In the AMA, policy follows science: a case history of tobacco
Authors: G. D. Lundberg
Journal: JAMA (1985)

In the evolution of health policy we can trace a cycle beginning with need, followed by a perception of that need, leading to questions (see Fig 1). The questions result in the challenge of thinking and research, generating data, which become information and are distributed. Over time, new knowledge may lead to changed attitudes. As some individuals change, they work to change the policies and practices of their institutions so they will reflect the new knowledge. Those whose attitudes have not changed will resist policy changes, and a struggle follows. If the force of the new knowledge and attitudes is strong enough, new policies will result. These will be followed by the implementation of new procedures, their subsequent evaluation, and further questions. The process cycles endlessly as humans and systems cycle. Subsequently changing human behavior on a large scale is perhaps the most difficult change, and it may happen slowly
Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice
Authors: Ping He, Zhenyu Zhong, Kristina Lindholm, Lilian Berning, Wendy Lee, Cynthia Lemere, Matthias Staufenbiel, Rena Li, Yong Shen
Journal: The Journal of Experimental Medicine (2007)
Antibodies to Thyroid Peroxidase Arise Spontaneously with Age in NOD.H-2h4 Mice and Appear after Thyroglobulin Antibodies
Authors: Chun-Rong Chen, Sepehr Hamidi, Helen Braley-Mullen, Yuji Nagayama, Catherine Bresee, Holly A. Aliesky, Basil Rapoport, Sandra M. McLachlan
Journal: Endocrine Reviews (2010)

Abstract Hashimoto’s thyroiditis, a common autoimmune disease, is associated with autoantibodies to thyroglobulin (Tg) and thyroid peroxidase (TPO). TPO, unlike abundant and easily purified Tg, is rarely investigated as an autoantigen in animals. We asked whether antibodies (Abs) develop to both TPO and Tg in thyroiditis in mice that is induced (C57BL/6 and DBA/1 strains) or arises spontaneously (NOD.H-2h4). Screening for TPOAbs was performed by flow cytometry using mouse TPO-expressing eukaryotic cells. Sera were also tested for binding to purified mouse Tg and human TPO. The antibody data were compared with the extent of thyroiditis. Immunization with mouse TPO adenovirus broke self-tolerance to this protein in C57BL/6 mice, but thyroiditis was minimal and TgAbs were absent. In DBA/1 mice with extensive granulomatous thyroiditis induced by Tg immunization, TPOAbs were virtually absent despite high levels of TgAbs. In contrast, antibodies to mouse TPO, with minimal cross-reactivity with human TPO, arose spontaneously in older (7–12 months) NOD.H-2h4 mice. Unexpectedly, TgAbs preceded TPOAbs, a time course paralleled in relatives of probands with juvenile Hashimoto’s thyroiditis. These findings demonstrate a novel aspect of murine and human thyroid autoimmunity, namely breaking B cell self-tolerance occurs first for Tg and subsequently for TPO.
Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.
Authors: Alicia Hurtado, Jesús García-Donas, Laia Garrigos, Nuria Laínez, Andres Redondo, Juan Fernando Cueva, Ana Santaballa, Maria Jesus Rubio, Isabel Palacio, Isabel Bover, Jose Antonio Lopez-Guerrero, Mario Prieto, Zaida Garcia-Casado, Susana Hernando Polo, Nuria Romero, Enrique Grande
Journal: Journal of Clinical Oncology (2014)

TPS5626 Background: Granulosa-cell tumors (GCT) of the ovary are a rare entity characterized by its genomic stability. A punctual mutation at the FOXL2 gene 402C→G (C134W) is present in up to 90% of cases. FOXL2 is a transcription factor that physiologically regulates the expression of the Steroidogenic Factor-1 (SF-1). This factor is known downregulate the expression of the enzyme CYP17 (key in androgens and 17-OH-progesterone synthesis). Thus FOXL2 mutations could impact hormonal synthesis by CYP17 in GCT. In fact, a previous study by our group has found clinical activity of ketoconazole, a well known CYP17 inhibitor, in this tumor (GREKO I trial). Orteronel (TAK700) is a selective inhibitor of 17, 20-lyase, that is being developed as an endocrine therapy for relevant hormone-sensitive cancers such as prostate and breast cancer. Orteronel is expected to suppress sex hormone levels in both circulation and relevant hormone-dependent malignant tissue. Thus we aimed to test the clinical activity of such drug in GCT. Methods: An open-label phase II single arm clinical trial has been designed for women with metastatic or locally advanced nonresectable granulosa cell ovarian tumor that harbors the somatic mutation FOXL2 402C→G (C134W) and who have not received prior treatment with any CYP17 inhibitor. Treatment will consist on Orteronel 300mg BID, given orally, continuously in a 28-day treatment cycle. The primary objective is to assess the clinical benefit rate. Since this is an extremely unfrequent disease, 10 Spanish institutions will get involved. The active support of a big collaborative group (GETHI) will guarantee candidates to be refereed to such institutions. An extensive translational research will be included in order to improve our scarce knowledge of GCT. Clinical trial information: 2013-003128-35.
Abstract 2475: FLT3-Explorer: A bioinformatics pipeline for detecting low signal in <i>FLT3</i> internal tandem duplications in acute myeloid leukemia
Authors: Christian Laing, Wenge Shi, Reinhold Pollner
Journal: Cancer Research (2019)

Abstract Introduction. Acute Myeloid Leukemia (AML) is the most common acute Leukemia among adults with a poor overall prognosis. With over 20,000 cases in the US alone, about a third of AML patients pertain to an important oncogenic driver composed of internal tandem duplication (ITD) somatic mutations in exons 14 and 15 of the FMS-like tyrosine kinase 3 (FLT3) gene. Detecting the presence of measurable residual disease in patients with AML who are in morphologic remission has been shown to be a powerful predictor of eventual relapse. Yet, despite its importance, the ability to detect FLT3-ITD mutations is hampered by the limited sensitivity of conventional PCR-based assays in general and in Next Generation Sequencing-based assays, in part due to the difficulty to align ITD-containing reads to the reference genome. Methods. In order to facilitate the analysis of AML samples, we developed FLT3-Explorer, a comprehensive bioinformatics pipeline composed of open source software, combined with in-house algorithms to accurately detect low levels of FLT3-ITD mutations. The input of the pipeline is unmapped reads in fastq format. The pipeline then searches for either ITD sequences previously observed in our extensive database of historical data, or a de-novo detection procedure is used to determine mutation sequences of variable lengths within the FLT3 gene. To assess the performance of FLT3-Explorer, we considered a cohort of clinical samples from bone marrow and peripheral blood, as well as cell lines. For sample collection, genomic DNA was isolated, and polymerase chain reaction was performed using primers flanking exons 13 and 15 to amplify the FLT3 gene. DNA was then sequenced using NGS Illumina sequencing. Results were validated using fragment size analysis by Capillary Electrophoresis assays. Also, to determine the limits of detection, various dilutions were performed on cell lines. Furthermore, to assess the performance of our pipeline, we performed a comparison with other FLT3-ITD programs publicly available. Summary. Results from our analysis showed that our method identifies FLT3-ITD mutations of variant allele fraction as low as 0.003%. Also, we found that our pipeline can detect as many FLT3-ITD mutants as other methods, or more, when the mutant signal is considerably low. Conclusions. FLT3-Explorer constitutes a powerful solution for low FLT3-ITD detection signal of mutant sequences, of diverse lengths, that can be used on FLT3-ITD AML patients to track disease progression and relapse. Citation Format: Christian Laing, Wenge Shi, Reinhold Pollner. FLT3-Explorer: A bioinformatics pipeline for detecting low signal in FLT3 internal tandem duplications in acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2475.
Woman's Auxiliary
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Physician response to computer reminders
Authors: C. J. McDonald
Journal: JAMA (1980)

A computerized medical record system was designed to detect and remind the responsible clinician about clinical events that might need corrective action. These reminders significantly increased the clinician response rate (in terms of test orders and treatment changes) to the events in question. The addition of relevant medical literature citations to the reminders did not significantly change the clinician response rate as compared with that with reminders alone, nor did it stimulate the physicians to read any of the cited articles kept in an immediately available "library" of reprints. (<i>JAMA</i>244:1579-1581, 1980)
Labetalol for Hypertension
Authors: John Kern
Journal: JAMA (1985)

<h3>To the Editor.—</h3> Labetalol hydrochloride (Normodyne) is an adrenergic blocking agent with both selective α<sub>1</sub>- and nonselective β-adrenergic blocking activity. The drug has been recently introduced in the United States for treatment of hypertension and is available in 200-mg tablets. The recommended starting dosage is 100 mg twice a day. <h3>Study.—</h3> In our initial series of 30 patients, the drug used as a single medication has been found to be efficient in lowering both systolic and diastolic pressure. However, in three patients use of the drug had to be discontinued because of cardiac arrhythmias. The nature of the arrhythmia could be determined in one patient only. This patient's electrocardiogram demonstrated premature atrial contractions with aberrant conduction (right bundle-branch block pattern). In all three affected patients, the arrhythmia occurred immediately after initiation of the therapy and was reversible upon its discontinuation. All three patients in whom it occurred were aged
ENTEROPTOSIS AND EXOPHTHALMIC GOITRE.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Les pancréatites aigües chirurgicales.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Radionuclide demonstration of peritoneal-pleural communication as a cause for pleural fluid
Authors: N. Datta
Journal: JAMA (1984)

<h3>To the Editor.—</h3> When pleural and peritoneal effusions occur simultaneously, it may be difficult to decide if the pleural fluid comes from the abdomen or whether there is separate disease in the chest. In this case a radionuclide study of the dynamics of peritoneal fluid transport may help. We recently encountered a case of pleural peritoneal communication. <h3>Report of a Case.—</h3> A woman 16 weeks pregnant had intraperitoneal hemorrhage caused by bilateral rupture of the uterine arteries and simultaneous appearance of fluid in the right pleural cavity. A right thoracentesis showed bloody pleural fluid with the same chemical contents as the peritoneal fluid. Five millicuries of technetium Tc 99m human serum albumin (HSA) instilled into the peritoneal cavity promptly migrated to the diaphragmatic level. After one hour, filling of a large right thoracic lymphatic channel emptying into the right subclavian vein as well as minimal accumulation in the pleural space
Pheochromocytoma
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hypocalcemia, Not Hypoglycemia.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal